- Home
- AKTX vs OMIC Comparison
AKTX vs OMIC Comparison
Compare AKTX & OMIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- OMIC
- Stock Information
- Founded
- AKTX N/A
- OMIC 2016
- Country
- AKTX United States
- OMIC United States
- Employees
- AKTX N/A
- OMIC N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- OMIC Medical/Dental Instruments
- Sector
- AKTX Health Care
- OMIC Health Care
- Exchange
- AKTX Nasdaq
- OMIC Nasdaq
- Market Cap
- AKTX 29.5M
- OMIC 34.9M
- IPO Year
- AKTX N/A
- OMIC 2021
- Fundamental
- Price
- AKTX $0.98
- OMIC $19.42
- Analyst Decision
- AKTX
- OMIC Hold
- Analyst Count
- AKTX 0
- OMIC 2
- Target Price
- AKTX N/A
- OMIC $10.75
- AVG Volume (30 Days)
- AKTX 54.0K
- OMIC 19.5K
- Earning Date
- AKTX 02-15-2025
- OMIC 11-12-2024
- Dividend Yield
- AKTX N/A
- OMIC N/A
- EPS Growth
- AKTX N/A
- OMIC N/A
- EPS
- AKTX N/A
- OMIC N/A
- Revenue
- AKTX N/A
- OMIC $2,667,000.00
- Revenue This Year
- AKTX N/A
- OMIC $3.98
- Revenue Next Year
- AKTX N/A
- OMIC $242.05
- P/E Ratio
- AKTX N/A
- OMIC N/A
- Revenue Growth
- AKTX N/A
- OMIC 2.77
- 52 Week Low
- AKTX $0.90
- OMIC $5.34
- 52 Week High
- AKTX $4.40
- OMIC $23.41
- Technical
- Relative Strength Index (RSI)
- AKTX 32.85
- OMIC 44.93
- Support Level
- AKTX $0.94
- OMIC $19.00
- Resistance Level
- AKTX $1.04
- OMIC $20.55
- Average True Range (ATR)
- AKTX 0.12
- OMIC 0.81
- MACD
- AKTX 0.04
- OMIC -0.22
- Stochastic Oscillator
- AKTX 11.11
- OMIC 14.48
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About OMIC Singular Genomics Systems Inc.
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.